AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis

UC Is Final Planned Indication For IL-23 Inhibitor

 
• By Mandy Jackson
Check marks on four wooden blocks
Ulcerative colitis is the fourth and final indication for Skyrizi • Source: Shutterstock

More from Clinical Trials

More from R&D